• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    PCI Pharma Services

    Aphena Pharma Solutions

    Emergent BioSolutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Almac Group

    Alcami

    Syngene

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Probing the Limits of Pharma’s Future

    A retrospective on the past 20 years and a prospective on where the future will take us.

    Probing the Limits of Pharma’s Future
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    • Adare Pharma Solutions
    Ben Locwin, Contributing Writer10.15.19
    Where have we tread? There has been, as you know, tremendous change in the industry of pharmaceutical medicine over the past 20 years. This has come in the form of increased growth and refinement of biologics, where 20 years ago the segment representing monoclonal antibody treatments was incredibly nascent. To have imagined 20 years ago that several of our industry’s Top 10-selling therapies would be biologics would have been considered predictive overreach.

    Within small molecules, much more refined molecular screening approaches have taken root, as our ability to resolve multidimensional aspects of complex chemistry has improved, and this has led to much more precisely-targeting treatments—approaching a more precision-medicine paradigm—as well as digging deeper into the dark corners of under-served diseases and orphan designations. This has meant that hundreds of thousands of discrete patients have been helped in the past two decades by the expansion into rarer indications.

    We have cell therapies and gene therapies, which were indeed predicted and researched over 20 years ago, but for which we had insufficient means to investigate these approaches and scale them up into a commercially-viable treatment option. These two new avenues of treatment have dominated the news cycles over the past couple years, but the development and clinical trials have in reality been ongoing for over a decade.

    And so it goes, we live and work within an industry which asks so much of us to pioneer the future, but from which we don’t get public exposure for many years. And this is not an admonishment about the current state of our industry, but I think an important point that all of the employees who work within pharmaceuticals are therefore absolutely NOT doing it for immediate gratification. Once our newest frontiers of treatment reach the market, we often aren’t interested in fanfare, because we’re already several years into the next approaches which will define the subsequent treatment epoch.

    What we thought would be
    If we don’t look with clear eyes at where we’ve stumbled, we’re not being honest with ourselves, nor in a position to improve our models to further ensure a better future for the industry and the treatment of complex diseases. To this end, we’ve had some misses, for example within personalized medicine. We’ve come to understand recently that a host of genes that we have assumed for many years were essential for tumor survival, actually aren’t. This should be considered a scientific win; for when we are able to collect contemporary data which overthrow previous convictions, and change our opinions accordingly, we are embodying the scientific method at its very heart. Our hypotheses are only as good as their most recently-survived falsifications. 

    “For when we are able to collect contemporary data which overthrow previous convictions - and change our opinions accordingly - we are embodying the scientific method at its very heart.”

    There are some who also look at where we stand with genetic analyses and think that we’ve missed fertile ground or opportunities haven’t been as newsworthy as they might have been. There is still much to do and much to learn in this field, and we continue to learn more and refine our thinking (more on this below). However, an issue that needs attention, but has received virtually none to date, is that of attributes of twin studies and over-extension of findings. This is due in large part to multidimensionality of the analyses needed and, as Nassim Nicholas Taleb conjectures, the influence dominance of convexity.

    In 2003, by the way, we thought the respiratory illness SARS would be an annually-recurring pandemic. And because a 20-year retrospective does indeed envelop January 1, 2000, remember that a not-insignificant proportion of everybody though all electronics were going to shut down for Y2K.

    But we seem to think that crazy ideas don’t seem so crazy after a while. This is called The Overton Window. However, the OW itself was just a specification of the psychology of normalization of group ideas, similar to the negative aspects of groupthink.

    Data are never perfect, but our approach to research can always improve
    Waiting for better-and-better data to come from our experiments (data quality approaching infinity) has diminishing returns. But until we have very well-refined models, we can, as a result of our ignorance, commit more errors in deploying our scientific ideas in a practical sense. This can lead to unintended effects like leading researchers to unleash millions of genetically-modified mosquitos and presumed-sterile mosquitos to Jacobino, Brasil, to abate the spread of mosquito-vectored diseases like Zika and Dengue.

    The word “presumed” is the trouble with the phrase in the previous sentence. Instead, what has been found is that after a period of mosquito population decrease, which was the desired effect, the indigenous mosquitos have rebounded and are indeed interbreeding inexplicably with the genetically-modified mosquitos—the unexpected and totally undesired effect. This is strikingly similar to Dr. Ian Malcolm’s quote from Jurassic Park: “Life finds a way.”*

    Yale University researcher Jeffrey Powell, who was part of recent reviews of the situation said, “It is the unanticipated outcome that is concerning.” Another newsworthy event hiding behind the principle of: ‘we couldn’t have predicted it.’ But could we have? If the research continued on to greater depth—prior to introduction of Aedes aegypti to the wild—to include other potential factors, clearly the interbreeding could have been predicted, experimentally-sampled, and included in the risk:benefit analysis.


    A human melanoma cell during division. Image by Paul J. Smit, Rachel Errington/Wellcome.

    A similar finding in our depth of belief and conviction in ideas we’ve held can be evidenced by recent experimental results showing that genes we thought were essential to oncogenesis really aren’t. Here’s the background: By interrogating what DNA is essential to oncogenesis and maintenance of cancer cells provides a treasure trove of information for drug developers to transform into new drug targets. If you were to look meta-analytically at hundreds of studies which pointed to certain proteins that seemingly needed to be present for cancer cell survival, you might think you had exactly the set of targets for your next-generational armamentarium. But you would be incorrect.

    This investigative work was done, in part by Jason Sheltzer and his team, on chemotherapeutic targets that appeared time and again in almost 200 research studies. After employing CRISPR genome editing to eliminate the genetic sources of these assumed-to-be-critical-proteins (the growth protein MELK), the cancer cells continued to persist. This is important information, because null results are just as important, and in some cases, insidiously more so, as positive results. They tell us about gaps in our knowledge and underlying hypotheses.

    In totality, CRISPR modification and 6 target proteins found with RNAi methods for oncology treatment were compared against 10 drugs which were intended to target these discrete molecular targets. It appears to be that how the cancer treatments are actually functioning to destroy tumor cells isn’t what was presumed. 

    And what of the future?
    I’d be remiss in talking of the future without mentioning artificial intelligence (AI), machine learning (ML), deep learning (DL), and quantum computing. All of these methods are in-use at various scales. We will indeed see more-and-more utility with AI in pharma, and more valuably, by harnessing the subsets within AI of machine learning and deep learning for pharma clinical data. These neural networks and algorithms can already outperform skilled, trained humans for highly-specified and -specialized tasks. For example, I’ve written before (Contract Pharma, July/Aug 2019) on the breakthroughs in these computer-based technologies in outperforming radiologists. In fact, deep learning has just been used to better visualize mechanisms within cells, in this case, mitochondria dynamics.


    Still frames of intercellular dynamics, with the right-side image enhanced by deep learning software. Image from Manor Lab, WABC/Salk Institute.

    Deep learning approaches have also recently been reported to be ~30% more accurate than humans at analyzing dark matter signals in composite maps of the cosmos.


    If you suspend your disbelief (or remain scale-agnostic), you might think these two previous images (cell interior and cosmic-scale galaxy-mapping) come from the same data sets.

    Quantum computing is the next frontier of which we are pushing the boundary.** I follow the updates daily in this space, and have participated on several developmental panels. As of the day of writing this, our boundary of humanity is a 53-qubit quantum computer built and being tested for client use by IBM. I can recommend some reading for you on this topic (see below), but suffice it to say that our current-generational computing power, which has largely been following, and constrained by, Moore’s Law, will perform a radical scale-shift in the next decade as we get more facile at harnessing quantum computing for practical use. We will then be able to think beyond the technological restraints we have now, because we’ll have available computing power that we can’t even at the moment begin to ask worthwhile questions to harness. The technology itself will push back on us as a species to come up with ‘smarter’ and ‘better’ questions in a nearly-limitless information feedback loop.


    First-ever image of quantum entanglement.

    We need to not forget about the inertia present in people within organizations. The hardest part of implementation of AI is not the technology, it’s the people. This was a paraphrase of a statement I made at an AI and Machine Learning conference, which was, “Culture trumps AI: The inertia that exists within organizational culture is the most significant impediment to the appropriate infusion of AI/ML into our work functions.”

    I think the other biggest factor is getting adopters to think differently than they have. If we’re encumbered by our old ways of thinking, approaching problems, and how to ask questions, we can’t fully utilize what AI, ML, and DL have to offer us. Especially in a more data-rich future. 

    *This was actually penned by Michael Crichton, the author of Jurassic Park, as “life will find a way.”
    **Until you opened the magazine to find this article, Erwin Schrödinger would have opined that perhaps it was in a state of both ‘written’ and ‘unwritten’ simultaneously. Thank you for collapsing its wave function.


    Further Reading
    • Gribbin, J. (1984). In Search of Schrödinger’s Cat: Quantum Physics and Reality. Bantam.
    • Rieffel, E. & Polak, W. (2011). Quantum Computing: A Gentle Introduction. MIT Press. (Author’s note: available for free at: http://mmrc.amss.cas.cn/tlb/201702/W020170224608150244118.pdf).
    • Fountaine, T., McCarthy, B., & Saleh, T. (2019). Building the AI-Powered Organization. Harvard Business Review. July/August 2019.


    Ben Locwin

    Ben Locwin, PhD, MBA, MS, MBB is a Healthcare Futurist, medical policy advisor, and public speaker. Annually he is commissioned to do a circuit on the future of various industries. “Importantly,” Dr. Locwin says, “looking back at the veracity of prior predictions and refining mental models is the only way to objectively get better at it.”
    Related Searches
    • expansion
    • artificial intelligence
    • Clinical Trials
    • software
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Adare Pharma Solutions Adare Pharma Solutions
    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    CONTRACT PHARMA Adds Media Sales Directors CONTRACT PHARMA Adds Media Sales Directors
    Like It’s 1999 Like It’s 1999
    20 Year Retrospective 20 Year Retrospective
    VIDEO: Alcami VIDEO: Alcami's Brittany Jackway
    VIDEO: Contract Pharma 2019 Video Highlights! VIDEO: Contract Pharma 2019 Video Highlights!
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda
    Who’s Irrational? Who’s Irrational?
    It’s Showtime! It’s Showtime!
    Artificial Intelligence and Machine Learning in Healthcare Artificial Intelligence and Machine Learning in Healthcare

    Related Columns

    • Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown and Joe Rymsza, IQVIA 03.01.21

    • Drug Discovery | Information Technology
      Artificial Intelligence and Machine Learning in Healthcare

      Artificial Intelligence and Machine Learning in Healthcare

      Because your summertime reading should make you a little uncomfortable.
      Ben Locwin, PhD, MBA, MS, Contributing Editor 07.15.19

    • Information Technology
      My Head is in The Cloud(s)

      My Head is in The Cloud(s)

      Cloud computing is making it easier to control all aspects of the global pharma production process
      Emil W. Ciurczak, DoraMaxx Consulting 05.07.19


    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18

    • Information Technology
      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA
      Robert Marohn, ClinLogic, LLC 04.10.18

    • cGMP Manufacture | Information Technology
      Flexible Manufacturing Strategies and Data Integrity

      Flexible Manufacturing Strategies and Data Integrity

      Making processes integral with your data handling ability
      Emil W. Ciurczak, DoraMaxx Consulting 11.07.17


    • APIs | Information Technology
      India’s Pharmaceutical Industry Outlook

      India’s Pharmaceutical Industry Outlook

      Market predicted to be worth $50B by 2020
      Dr. Gurpreet Sandhu, Reva Pharmachem 03.06.15

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login